|
Isis Pharmaceuticals is trying to make sense out of antisense. The biotechnology company is developing drug therapies based on antisense technology, in which drugs attach themselves to strands of RNA in order to prevent them from producing disease-causing proteins; the hoped-for end result is a therapy that fights disease without harming healthy cells. Isis Pharmaceuticals works by discovering potential compounds (primarily in the areas of cardiovascular and metabolic disease but also in a range of other categories) and finding larger pharmaceutical partners to license the drugs or collaborate in their development. Its lead candidate is high cholesterol drug mipomersen, which Isis has licensed to Genzyme.
|
| | | Contact Information | |
Address: |
1896 Rutherford Rd.
Carlsbad, CA 92008-7326
| | Phone: | 760-931-9200 | | Fax: | 760-603-2700 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 107.20 M | | Revenue Growth (1 yr): | 54.00% | | Employees (2008): | 300 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman, President, and CEO:
Stanley T. Crooke
| | • |
COO, CFO, Secretary, and Director:
B. Lynne Parshall
| | • |
Director, Corporate Communications:
Kristina Lemonidis
|
|
|
